drugset / Trial / NCT04213196

Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

NCT04213196

RandomizedParallel-groupDouble-blindOther

Summary

This is a first-in-human, Phase I, single-dose escalation clinical trial conducted in Chinese healthy volunteers. The safety, tolerability, and PK of HSK21542 injection in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design

Timeline

Start
2020-01-09
Primary completion
2020-09-06
Completion
2020-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK21542 Peptide 0.2 ug/kg Intravenous
Subject HSK21542 Peptide 0.5 ug/kg Intravenous
Subject HSK21542 Peptide 0.75 ug/kg Intravenous
Subject HSK21542 Peptide 1 ug/kg Intravenous
Subject HSK21542 Peptide 1.5 ug/kg Intravenous
Subject HSK21542 Peptide 2.25 ug/kg Intravenous
Subject HSK21542 Peptide 3.375 ug/kg Intravenous

Indications

No indication recorded.